Everand Logo

Welcome to Everand!

  • STAT

    Cholesterol drug significantly reduced patients’ risk of death in trial, a boon for Sanofi and Regeneron

    A cholesterol drug from Sanofi and Regeneron significantly reduced patients’ risk of death in a clinical trial, giving them a boost over rival Amgen.
    by Damian Garde Mar 10, 2018 2 minutes
    Source: APStock

    A cholesterol drug from Regeneron Pharmaceuticals and Sanofi reduced patients’ risk of death in a major clinical trial, giving the companies a boost over rival Amgen and stoking hopes that the costly medicine might finally find commercial success.

    The treatment, called Praluent, reduced the risk of death by 15 percent in a study involving 18,000 high-risk patients who had uncontrolled cholesterol despite taking a maximum amount of statins like

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
    A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
    STAT1 min read
    USDA Faulted For Disclosing Scant Information About Outbreaks Of H5N1 Avian Flu In Cattle
    With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.
    STAT1 min read
    Opinion: STAT+: How AI Can Help Satisfy FDA’s Drug, Device Diversity Requirements
    To meet the Food and Drug Omnibus Reform Act, companies must rethink their current clinical trial strategies. Including AI and machine learning approaches can help.

    Related Books & Audiobooks